Sensus Healthcare, Inc. (SRTS) SEC Filings

Sensus Healthcare, Inc. (SRTS) director Eric Sachetta reported open-market purchases of the company’s common stock. On August 27, 2026, he purchased 10,925 shares at $3.181 per share, and on August 26, 2026 he purchased 9,708 shares at $3.289 per share, for a total of 20,633 shares acquired directly. The filing also reports an indirect holding of 2,093 shares held through his spouse.

Sensus Healthcare, Inc. (SRTS) director Eric Sachetta reported an open-market purchase of the company’s Common Stock. On 2026-08-24, he purchased 34,697 shares at a price of $3.254 per share, bringing his directly held position to 209,310 shares. He also reports 2,093 shares held indirectly through his spouse.

Sensus Healthcare, Inc. (SRTS) reported that its Chief Executive Officer and director, Joseph C. Sardano, purchased 20,000 shares of common stock on 2026-08-20 in an open-market or private transaction at $3.0243 per share. Following this transaction, he directly owns 1,220,293 shares of SRTS common stock.

Sensus Healthcare, Inc. (SRTS) director Eric Sachetta reported open-market purchases of 31,000 shares of common stock. He bought 24,000 shares on August 20, 2026 at $3.1280 per share and 7,000 shares on August 21, 2026 at $3.2540 per share, all held directly. A separate entry shows 2,093 shares held indirectly through his spouse. The filing indicates these transactions were not made pursuant to a Rule 10b5-1 trading plan.

Sensus Healthcare, Inc. reported sharply weaker results for the quarter ended June 30, 2026. Revenue fell to $2.3 million from $7.3 million a year earlier, mainly due to fewer systems sold, no sales to a historically large U.S. customer, and more systems placed under Fair Deal and rental arrangements that recognize revenue over time.

Gross margin declined to 34.8%, and the company posted a quarterly net loss of $8.7 million, or $(0.53) per share. For the first six months, revenue was $5.7 million versus $15.7 million, with a net loss of $11.4 million. Management recorded a valuation allowance that eliminated the deferred tax asset, driving income tax expense of $5.7 million in the quarter and turning retained earnings into an accumulated deficit.

Cash, restricted cash, and equivalents declined to $15.2 million from $22.1 million as the business used $6.9 million in operating cash, while inventories increased to $18.5 million. The company has no debt outstanding and a new $15.0 million revolving credit facility with City National Bank of Florida, initially limiting borrowings to $2.0 million and secured by $2.2 million of restricted cash.

Sensus Healthcare reported weak results for the three months ended June 30, 2026, as revenue fell to $2.3 million from $7.3 million a year earlier, a 68.5% decrease. Management attributed the decline mainly to fewer units sold, no sales to a historically large customer, and greater use of Fair Deal Agreements and rentals, which shift revenue recognition over time. Revenue on eight purchased units was deferred to the third quarter due to financing approval timing.

Gross profit declined to $0.8 million with margin of 34.8%, down from 39.7%, reflecting product mix, more international shipments, and upfront costs on Fair Deal placements. Operating expenses fell across general and administrative, selling and marketing, and research and development, yet a $5.7 million tax valuation allowance drove net loss to $8.7 million (or $0.53 per share) versus a $1.0 million loss (or $0.06 per share) last year. Adjusted EBITDA was a negative $3.0 million.

Cash, restricted cash and cash equivalents were $15.2 million as of June 30, 2026, down from $22.1 million at year-end, with no borrowings on the revolving credit line. The company highlighted commercial momentum supported by dedicated CPT codes and noted that CMS has proposed a 26% increase in a hospital-based delivery code, which it views as enhancing the reimbursement outlook for its superficial radiotherapy systems.

Sensus Healthcare, Inc. entered into a new revolving credit facility with City National Bank of Florida, providing up to $15,000,000 in borrowings. The loan bears interest at the Secured Overnight Financing Rate plus 3% per annum and matures on June 5, 2027, unless extended by mutual agreement.

The facility is secured by $2,230,000 in cash collateral and a security interest in all of the company’s assets. The agreement restricts asset sales outside the ordinary course, additional indebtedness, new liens, and removal of the CEO, President, or CFO without the bank’s consent. Sensus must maintain a minimum debt service coverage ratio of 1.50, with customary default provisions that allow the bank to accelerate the loan and exercise remedies against collateral.

Sensus Healthcare, Inc. reported the results of its Annual Meeting of Stockholders held on May 29, 2026. Stockholders elected incumbent Class II directors Eric Sachetta and Michael J. Sardano to three-year terms expiring in 2029.

For the director elections, Sachetta received 5,532,247 votes for, 516,567 against, 270,440 abstentions, and 5,000,719 broker non-votes. Sardano received 4,702,852 votes for, 1,346,063 against, 270,339 abstentions, and 5,000,719 broker non-votes.

Stockholders also approved, on a non-binding advisory basis, the 2025 executive compensation program, with 4,740,572 votes for, 856,128 against, 722,554 abstentions, and 5,000,719 broker non-votes. In addition, stockholders ratified the appointment of Carr, Riggs & Ingram, LLC as independent registered public accountant for the year ending December 31, 2026, with 10,738,792 votes for, 148,466 against, and 432,715 abstentions.